Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7033550 | 0.80 | CYP3A4 (0.54) | CYP3A4NAMPTXDHMEN1KMT2A | |
| SCHEMBL27476007 | 0.76 | MEN1 (0.60) | CYP3A4NAMPTXDHMEN1KMT2A | |
| SCHEMBL15022727 | 0.76 | CYP3A4 (0.54) | CYP3A4NAMPTXDHMEN1KMT2A | |
| SCHEMBL2919937 | 0.76 | CYP3A4 (0.50) | CYP3A4NAMPTXDHMEN1KMT2A | |
| SCHEMBL2919854 | 0.76 | CYP3A4 (0.46) | CYP3A4NAMPTXDHMEN1KMT2A | |
| SCHEMBL2921100 | 0.75 | PKM (0.39) | MEN1KMT2APOLBHTTPKM | |
| SCHEMBL30805800 | 0.75 | CYP3A4 (0.49) | CYP3A4NAMPTXDHMEN1KMT2A | |
| SCHEMBL4287528 | 0.74 | CYP3A4 (0.51) | CYP3A4NAMPTXDHMEN1KMT2A | |
| SCHEMBL2915004 | 0.72 | PNP (0.42) | MEN1KMT2APOLBHTTPARP1 | |
| SCHEMBL12999419 | 0.71 | CYP3A4 (0.46) | CYP3A4NAMPTXDHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009084695-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | CYP3A4 3334/4885NAMPT 4195/4885XDH 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.